A study to compare norursodeoxycholic acid with placebo in the treatment of primary sclerosing cholangitis A study to compare norursodeoxycholic acid with placebo in the treatment of primary sclerosing chola ...
Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis - NUC-5/PSC Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid caps ...
Primary Sclerosing Cholangitis (PSC) is a slowly progressing chronic cholestatic liver disease of assumed autoimmune, but finally unidentified etiology, characterized by a chronic inflammatory and fibro-obliterative destruction of extra-, and intrahepatic bile ducts. The disease is characterized by diffuse inflammation, fibrosis, and strictures of the intra- and/or extrahepatic bile ducts with an impaired biliary secretion of potentially aggressive bile fluid often leading to cirrhosis. MedDRA version: 20.1;Level: LLT;Classification code 10036732;Term: Primary sclerosing cholangitis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Primary Sclerosing Cholangitis (PSC) is a slowly progressing chronic cholestatic liver disease of as ...